Risk of cancer-specific, cardiovascular, and all-cause mortality among Asian and Pacific Islander breast cancer survivors in the United States, 1991–2011

Pooja A. Solanki1, Naomi Y. Ko2, Dima M. Qato1,3 and Gregory S. Calip3,4*

Abstract
Asian and Pacific Islander (API) women in the United States (U.S.) are a heterogeneous group reported to have better prognosis after breast cancer (BC) compared to their Non-Hispanic White (NHW) counterparts. Few studies have examined differences in BC survival between individual API ethnic groups. We conducted a retrospective cohort study of 462,005 NHW and 44,531 API women diagnosed with incident, stage I–III BC between 1991 and 2011 in the Surveillance, Epidemiology and End Results (SEER) 18 registries. SEER-reported API ethnicity was grouped as Chinese, Japanese, Filipino, Hawaiian, Korean, Vietnamese, Asian Indian and Pakistani, and Pacific Islander. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for risk of BC-specific, cardiovascular and all-cause mortality comparing API to NHW women. We also estimated mortality risk comparing U.S.-born to non-U.S.-born women. Compared to NHW women, API women overall had lower BC-specific, cardiovascular and all-cause mortality. BC-specific mortality risk was lowest among Japanese women (HR 0.69, 95% CI 0.63–0.77). Other women had similar (Filipino, HR 0.93, 0.86–1.00; Hawaiian, HR 1.01, 0.89–1.17) or greater (Pacific Islander, HR 1.44, 1.17–1.78) risk of BC-specific death. Compared to non-U.S. born API women, findings were suggestive of increased cardiovascular (HR 1.12, 1.03–1.20) and all-cause mortality (HR 1.29, 1.08–1.54) among U.S.-born API women. Mortality risk varies greatly between BC survivors from different API backgrounds. Further research is warranted to understand these disparities in BC survivorship and the social and cultural factors that possibly contribute to greater mortality among later-generation API women born in the United States.

Keywords: Breast cancer, Asian American, Pacific Islander, Cancer survivorship, Mortality

Background
Current understanding of breast cancer epidemiology among Asian women is limited due to the aggregation of data on Asian race and ethnicity. Asian and Pacific Islander (API) communities compose the fastest growing racial/ethnic group in the United States (U.S.) (U.S. Census Bureau 2012). This group originates from the earth’s largest continent and encompasses a heterogeneous population with respect to multiple races, immigration status, religion, specific cultural factors, health beliefs and health practices, including those related to cancer and cancer screening (Thompson et al. 2014; Sabatino et al. 2015; Kagawa-Singer and Pourat 2000; Gomez et al. 2004, 2007).

Breast cancer (BC) is the most frequently diagnosed cancer in women. Despite overall declines in BC over the past 5–10 years in other U.S. racial and ethnic groups, incidence rates among some but not all API ethnic groups show increasing trends (American Cancer Society 2013). API women overall are reported to have the highest 5-year survival rates after breast cancer (91.4 %), but these data are unreliable given this large heterogeneous
group. Even less is known about long-term outcomes among API breast cancer survivors in the U.S.

Across the Asian continent, cancer outcomes vary greatly by country and ethnicity. In a global surveillance assessment in 2010, the 5-year breast cancer survival rates in some Asian countries, including Japan, China, Taiwan, Indonesia, Korea, and Thailand, were greater than 80%. However, in India, survival rates are reported to be less than 60% (Allemani et al. 2015). The aggregation of these populations living in the U.S. into one group dilutes differences between distinct API ethnic groups that could explain differential cancer-specific mortality, cardiovascular mortality and all-cause mortality in API breast cancer survivors (Wu et al. 2013; Lin et al. 2002; Trinh et al. 2015). In prior studies of API women in the U.S., greatest survival is reported among Japanese women (Allemani et al. 2015), whereas Hawaiian and Filipino women experience poor breast cancer survival after diagnosis compared to NHW women (Meng et al. 1997; Hsu et al. 1997).

Few studies exist on differences in long-term survival after breast cancer by specific API ethnic groups in the U.S. Studies on cancer outcomes among Asian Americans tend to be limited by small sample sizes or represent only geographic areas in the U.S. with large API populations such as California. The collection of data on cancer incidence and follow up with information on specific API ethnic groups by U.S. population-based cancer registries in the Surveillance, Epidemiology and End Results (SEER) Program will increase our understanding of the heterogeneity of breast cancer in API women.

Our objective was to disaggregate the large and heterogeneous “Asian” group to determine differences in the risk of breast cancer-specific, cardiovascular and all-cause mortality among breast cancer survivors by API ethnicity. We further examined possible differences in mortality risk among API women born in the U.S. compared to non-U.S. born women.

Methods

Study population and data sources

We conducted a retrospective cohort study of women diagnosed with a first primary invasive, stage I–III breast cancer between January 1, 1991 and December 31, 2011 identified through twelve population-based cancer registries in the U.S. that participate in the National Cancer Institute’s SEER Program [Surveillance Epidemiology and End Results (SEER) Program (2013)]—those serving the geographic areas of San Francisco-Oakland, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle-Puget Sound, Utah, Atlanta, San Jose-Monterey, Los Angeles, Rural Georgia, California (excluding SF/SJM/LA), Kentucky, Louisiana, New Jersey and Greater Georgia. SEER ascertains and follows demographic and tumor-specific information including age at diagnosis, stage and vital status with detail on cause-specific death. Further details and methods used by the SEER Program are provided elsewhere (Lash et al. 2007).

A total of 462,005 NHW and 44,531 API women ages 20 years and older with invasive, stages I–III BC documented in SEER as their first primary cancer diagnosis (no history of cancer before index diagnosis) that received cancer-directed surgery were included in this study. Women were excluded if their cancer was diagnosed at autopsy and if their race was classified as other or unknown.

The primary exposure of interest was race and ethnicity. We used SEER-coded categories of race and ethnicity to classify study participants. We used these categorizations in our analyses to classify women into mutually exclusive categories of Non-Hispanic White and Asian/Pacific Islander. API ethnicity was disaggregated into groups reported as Chinese, Japanese, Filipino, Hawaiian, Korean, Vietnamese, Asian Indian and Pakistani, Pacific Islander and Other Asian. Pacific Islander women included those with ethnicity reported as Micronesian, Chamorroan, Guamanian NOS, Polynesian NOS, Tahitian, Samoan, Tongan, Melanesian NOS, Fiji Islander, New Guinean, and Other Pacific Islander. For purposes of small reported number of cases, women grouped as ‘Other Asian’ included Thai, Laotian, Hmong, Kambucan and unspecified other.

We ascertained data for this cohort of BC survivors from the SEER registries, including: age at diagnosis, year of diagnosis, American Joint Committee on Cancer (AJCC) stage (Singletary et al. 2003), estrogen receptor (ER) status, progesterone receptor (PR) status, tumor size, and lymph node status. Information on type of surgery and receipt of radiation treatment was obtained, but data on adjuvant chemotherapy and adjuvant hormonal therapy were not available. Data regarding other socioeconomic factors, such as income and health insurance status, were also not available. Women included were required to have cancer-directed surgery documented in SEER, classified as mastectomy (radical or total) or breast-conserving surgery (less than total mastectomy: segmental mastectomy, lumpectomy, quadrantectomy, tylectomy, wedge resection, nipple resection, excisional biopsy, or partial mastectomy NOS).

For a secondary analysis, we obtained SEER-documented place of birth for women as U.S. born, non-U.S. born and birthplace not specified or missing. Because the exposure of interest was U.S. born status within API race/ethnicity, we compared U.S.-born women to non-U.S. born, although this analysis was limited by unknown place of birth for 16,150 (36.3%) of API women.
Survival time was calculated in months from diagnosis to the date of death or to the date last known to be alive. The closure date for follow-up observation was December 31, 2012. The outcomes in these analyses, death due to breast cancer and death due to cardiovascular causes, were examined separately to account for competing causes of death which differed by ethnic group (Howlader et al. 2010). We also examined all-cause mortality without considering these competing risks. Breast cancer cases were considered to have experienced breast cancer-specific mortality if their cause of death was classified by International Classification of Diseases, Ninth Revision (ICD-9) codes as death due primary malignant breast cancer. The outcome of cardiovascular-specific mortality was similarly defined using ICD-9 codes for death due to diseases of the heart, hypertension without heart disease, cerebrovascular disease, atherosclerosis, aortic aneurysm and dissection and other diseases of arteries, arterioles and capillaries. Cases who died from other causes or were lost to follow-up were considered censored at the time of loss or death in cause-specific mortality analyses (Varadhan et al. 2010).

Survival analyses were performed using Cox proportional hazards models to calculate adjusted hazard ratio (HRs) and 95% confidence intervals (CIs) for risk of breast cancer-specific, cardiovascular and all-cause mortality comparing women of specific API ethnicities to NHW women. Mortality risks were estimated in models adjusting for year of diagnosis, SEER registry, age (20–49, 50–64, 65–74, 75–84, 85+ years) and AJCC stage (I, II, III) and in fully multivariable-adjusted models that included adjustment for confounding variables selected a priori, including, birthplace (U.S., non-U.S., unknown), marital status (single or never married, married or domestic partner, unknown), hormone receptor status (ER+/PR+, ER+/PR−, ER−/PR+, ER−/PR−, unknown), tumor size (<2, ≥2 cm, unknown), lymph node status (negative, positive, unknown), surgical procedure (radical or total mastectomy, breast-conserving surgery, unspecified surgery) and radiation (yes/no). Separate analyses within each API ethnicity examined the effect of U.S. birthplace by comparing the survival of women born in the U.S. to women not born in the U.S.

We evaluated proportional hazards assumptions by plotting the logarithm of the negative logarithm of the survival function over time. No evidence of violation of these assumptions was found. All analyses were performed using SAS statistical software version 9.3 (Cary, NC).

**Ethics, consent and permissions**

Approval was obtained from the Institutional Review Board at the University of Illinois at Chicago for this data analysis. No patient identifiers were included. Because information from SEER*Stat is de-identified and based on cancer registry data, it is not possible to seek informed consent from each participant, and we therefore received a waiver of consent.

**Results**

Descriptive characteristics of the 462,005 NHW and 44,531 API women diagnosed between 1991 and 2011 that were included in our analysis are reported in Table 1. Median age at diagnosis was higher among NHW women compared to API women overall. API women were more often non-U.S. born and had slightly greater proportions of women diagnosed with BC that was AJCC stage II or III, ER(−)/PR(−), and have positive lymph node status. More API women received radical or total mastectomy versus breast-conserving surgery. Among overall crude death rates by the end of follow-up, 23.8% of NHW women death due to any cause of which 42.0% were due to breast cancer and 23.2% were due to cardiovascular disease. Overall, 15.4% of API women experienced death due to any cause of which 53.3% were breast cancer-specific and 17.1% were due to cardiovascular disease. Descriptive characteristics of API women by ethnic group are reported in Table 2. Characteristics varied considerably by API ethnicity with median age at BC diagnosis being lowest among Korean, Vietnamese, Asian Indian and Pakistani women. Among API groups, Asian Indian and Pakistani women and Pacific Islander women had higher proportions of stage III BC at diagnosis (17.9% and 20.7%, respectively) compared to the proportion of NHW women diagnosed with stage III BC (12.8%).

Age-adjusted cumulative hazards of mortality among NHW and API women with BC are shown in Fig. 1 with the cumulative hazards disaggregated by API ethnicity shown in Fig. 2. Compared to NHW women, API women with BC had significantly lower risks of breast cancer-specific mortality (HR 0.88, 95% CI 0.84–0.93), cardiovascular mortality (HR 0.77, 95% CI 0.71–0.83) and all-cause mortality (HR 0.82, 95% CI 0.80–0.85). These associations differed by API ethnic group with some women having risk of breast cancer mortality similar to NHW women (Filipino, HR 0.93, 95% CI 0.86–1.00; Hawaiian, HR 1.01, 95% CI 0.89–1.17) and Pacific Islander women having significantly higher risk of breast cancer mortality (HR 1.44, 95% CI 1.17–1.78). Hawaiian women had higher risk of cardiovascular mortality (HR 1.43, 95% CI 1.17–1.75) and Pacific Islander women had higher risk of all-cause mortality (HR 1.53, 95% CI 1.30–1.75) compared to NHW women (Table 3).

In analyses comparing U.S. born API women to non-U.S. born API women, no statistically significant differences in risk were observed for breast cancer-specific mortality.
overall or within any specific API groups. However, U.S. born API breast cancer survivors overall had higher risk of cardiovascular mortality (HR 1.29, 95% CI 1.08–1.54) and all-cause mortality (HR 1.12, 95% CI 1.03–1.20) compared to non-U.S. born API breast cancer survivors. While estimates for some specific API groups were suggestive of increased all-cause mortality for U.S. born women (Filipino, HR 1.31, 95% CI 1.07–1.62; Asian Indian and Pakistani, HR 1.49, 95% CI 0.79–2.83), these differences in risk of breast cancer-specific, cardiovascular and all-cause mortality by U.S. birthplace were not significant within individual API groups of breast cancer survivors (Table 4).

**Discussion**

Asian and Pacific Islander women compose a diverse, large and growing population that has traditionally been studied as a single entity. We utilized a large, geographic population-based database to identify differences among this heterogeneous group. Although API women overall have lower breast cancer mortality, differences exist in health outcomes following breast cancer diagnoses depending on national origin (Gomez et al. 2014; Parise and Caggiano 2014; Telli et al. 2011; Yost et al. 2001). Our findings suggest that Pacific Islander women are at increased risk for all-cause and breast-cancer specific mortality relative to NHW women and other API

### Table 1 Descriptive characteristics of Non-Hispanic White and Asian/Pacific Islander women with stages I–III breast cancer in the SEER 18 registries, 1991–2011

|                     | Non-Hispanic White women (n = 462,005) | Asian/Pacific Islander women (n = 44,531) |
|---------------------|----------------------------------------|------------------------------------------|
| **Age at index breast cancer** |                                        |                                          |
| Mean (SD)           | 61.2 (13.7)                             | 56.3 (13.1)                              |
| Median (IQR)        | 61 (51–72)                              | 55 (46–66)                               |
| 20–49 years         | 102,558 (22.2)                          | 15,241 (34.2)                            |
| 50–64 years         | 168,817 (36.5)                          | 17,111 (38.4)                            |
| 65–74 years         | 100,839 (21.8)                          | 7683 (17.3)                              |
| 75–85 years         | 70,659 (15.3)                           | 3789 (8.5)                               |
| 85+ years           | 19,132 (4.1)                            | 707 (1.6)                                |
| **Years of diagnosis** |                                      |                                          |
| 1991–1995           | 57,530 (12.5)                           | 4646 (10.4)                              |
| 1996–2000           | 84,289 (18.2)                           | 8009 (18.0)                              |
| 2001–2005           | 145,993 (31.6)                          | 12,856 (28.9)                            |
| 2006–2011           | 174,193 (37.7)                          | 19,020 (42.7)                            |
| **Birthplace**      |                                        |                                          |
| U.S.                | 194,905 (42.2)                          | 8424 (18.9)                              |
| Non-U.S.            | 20,923 (4.5)                            | 19,957 (44.8)                            |
| Unknown             | 246,177                                 | 16,150                                   |
| **Marital status**  |                                        |                                          |
| Single or never married | 47,135 (10.2)                           | 5372 (12.1)                              |
| Married or domestic partner | 400,184 (86.6)                         | 38,178 (85.7)                            |
| Unknown             | 14,686                                  | 981                                      |
| **AJCC stage**      |                                        |                                          |
| I                   | 242,188 (52.4)                          | 21,664 (48.6)                            |
| II                  | 160,716 (34.8)                          | 16,855 (37.9)                            |
| III                 | 59,101 (12.8)                           | 6012 (13.5)                              |
| **Hormone receptor status** |                                    |                                          |
| ER(+)/PR(+)         | 282,720 (61.2)                          | 26,974 (60.6)                            |
| ER(+)/PR(−)         | 50,909 (11.0)                           | 4623 (10.4)                              |
| ER(−)/PR(+)         | 6931 (1.5)                              | 823 (1.8)                                |
| ER(−)/PR(−)         | 71,453 (15.5)                           | 7668 (17.2)                              |
| Missing             | 49,992                                  | 4443                                     |
| **Tumor size**      |                                        |                                          |
| <2 cm               | 365,185 (79.0)                          | 35,248 (79.2)                            |
| ≥2 cm               | 94,405 (20.4)                           | 9097 (20.4)                              |
| Missing             | 2415                                    | 186                                      |
| **Lymph node status** |                                    |                                          |
| Negative            | 315,405 (68.3)                          | 29,897 (67.1)                            |
| Positive            | 146,516 (31.7)                          | 14,625 (32.8)                            |
| Missing             | 84                                      | 9                                        |
| **Surgery**         |                                        |                                          |
| Radical or total mastectomy | 199,975 (43.3)                         | 22,558 (50.7)                            |
| Breast-conserving surgery | 223,197 (48.3)                      | 19,109 (42.9)                            |
| Unspecified surgery | 38,833                                  | 2864                                     |
| Radiation           | 213,565 (46.2)                          | 21,825 (49.0)                            |

---

a Asian/Pacific Islander includes women classified in SEER as Chinese, Japanese, Filipino, Hawaiian, Korean, Vietnamese, Laotian, Hmong, Kampuchean, Thai, Asian Indian, Pakistani, Micronesian, Chamoran, Guamanian NOS, Polynesian NOS, Tahitian, Samoan, Tongan, Melanesian NOS, Fiji Islander, New Guinean, Other Asian and Other Pacific Islander

**Table 1 continued**

|                     | Non-Hispanic White women (n = 462,005) | Asian/Pacific Islander women (n = 44,531) |
|---------------------|----------------------------------------|------------------------------------------|
| **Person-years of follow-up** |                                        |                                          |
| Mean (SD)           | 6.8 (4.9)                               | 6.7 (5.0)                                |
| Median (IQR)        | 4 (2–6)                                 | 3 (2–5)                                  |
| <2 years            | 80,086 (17.3)                           | 8754 (19.7)                              |
| 2–4 years           | 79,702 (17.3)                           | 7831 (17.6)                              |
| 4–6 years           | 70,179 (15.2)                           | 6605 (14.8)                              |
| 6–8 years           | 60,933 (13.2)                           | 5566 (12.5)                              |
| 8–10 years          | 54,674 (11.8)                           | 4700 (10.6)                              |
| 10+ years           | 116,431 (25.2)                          | 11,075 (24.9)                            |
| **Outcome status**  |                                        |                                          |
| Alive               | 352,200 (76.2)                          | 37,658 (84.6)                            |
| Died (all causes)   | 109,805 (23.8)                          | 6873 (15.4)                              |
| Breast cancer-specific | 46,116 (42.0)                        | 3661 (53.3)                              |
| Cardiovascular      | 25,527 (23.2)                           | 1173 (17.1)                              |
Table 2  Descriptive characteristics of women with stages I–III breast cancer by Asian/Pacific Islander ethnicity in the SEER 18 registries, 1991–2011

|                          | Non-Hispanic White women (n = 462,005) | Chinese (n = 8416) | Japanese (n = 7858) | Filipino (n = 11,193) | Hawaiian (n = 2569) |
|--------------------------|----------------------------------------|-------------------|---------------------|-----------------------|---------------------|
| Age at index breast cancer | Mean (SD)                              | 61.2 (13.7)        | 55.9 (13.5)         | 61.7 (13.6)           | 56.0 (12.1)         |
|                          | Median (IQR)                            | 61 (51–72)         | 54 (46–66)          | 62 (51–72)            | 55 (47–64)          |
| 20–49 years              | 102,558 (22.2)                          | 3164 (37.6)        | 1719 (21.9)         | 3628 (32.4)           | 761 (29.6)          |
| 50–64 years              | 168,817 (36.5)                          | 2972 (35.3)        | 2635 (33.5)         | 4793 (42.8)           | 1088 (42.4)         |
| 65–74 years              | 100,839 (21.8)                          | 1361 (16.2)        | 1937 (24.7)         | 1903 (17.0)           | 490 (19.1)          |
| 75–85 years              | 70,659 (15.3)                           | 746 (8.9)          | 1299 (16.5)         | 753 (6.7)             | 201 (7.8)           |
| 85+ years                | 19,132 (4.1)                            | 173 (2.1)          | 268 (3.4)           | 116 (1.0)             | 29 (1.1)            |
| Birthplace               |                                        |                   |                     |                       |                     |
| U.S.                     | 194,905 (42.2)                          | 930 (11.1)         | 3838 (48.8)         | 670 (6.0)             | 2078 (80.9)         |
| Non-U.S.                 | 20,923 (4.5)                            | 4398 (52.3)        | 1423 (18.1)         | 7339 (65.6)           | 22 (0.9)            |
| Unknown                  | 246,177                                 | 3088              | 2597                | 3184                  | 469                 |
| Marital status           |                                        |                   |                     |                       |                     |
| Single or never married  | 47,135 (10.2)                           | 994 (11.8)         | 972 (12.4)          | 1429 (12.8)           | 386 (15.0)          |
| Married or domestic partner | 400,184 (86.6)                        | 7252 (86.2)        | 6772 (86.2)         | 9523 (85.1)           | 2131 (83.0)         |
| Unknown                  | 14,686                                  | 170               | 114                 | 241                   | 52                  |
| AJCC stage               |                                        |                   |                     |                       |                     |
| I                        | 242,188 (52.4)                          | 4250 (50.5)        | 4624 (58.8)         | 5022 (44.9)           | 1221 (47.5)         |
| II                       | 160,716 (34.8)                          | 3128 (37.2)        | 2484 (31.6)         | 4442 (39.7)           | 959 (37.3)          |
| III                      | 59,101 (12.8)                           | 1038 (12.3)        | 750 (9.5)           | 1729 (15.4)           | 389 (15.1)          |
| Hormone receptor status  |                                        |                   |                     |                       |                     |
| ER(+/PR(+))              | 282,720 (61.2)                          | 5059 (60.1)        | 5083 (64.7)         | 6572 (58.7)           | 1775 (69.1)         |
| ER(+/PR(−))              | 50,909 (11.0)                           | 869 (10.3)         | 842 (10.7)          | 1226 (11.0)           | 224 (8.7)           |
| ER(−)/PR(+)              | 6031 (1.5)                              | 152 (1.8)          | 178 (2.3)           | 190 (1.7)             | 65 (2.5)            |
| ER(−)/PR(−)              | 71,453 (15.5)                           | 1445 (17.2)        | 1062 (13.5)         | 1977 (17.7)           | 371 (14.4)          |
| Missing                  | 49,992                                  | 891               | 693                 | 1228                  | 134                 |
| Tumor size               |                                        |                   |                     |                       |                     |
| <2 cm                    | 365,185 (79.0)                          | 6685 (79.4)        | 6259 (79.7)         | 8534 (76.2)           | 1911 (74.4)         |
| ≥2 cm                    | 94,405 (20.4)                           | 1695 (20.1)        | 1571 (20.0)         | 2613 (23.3)           | 651 (25.3)          |
| Missing                  | 2415                                    | 36                 | 28                  | 46                    | 7                   |
| Lymph node status        |                                        |                   |                     |                       |                     |
| Negative                 | 315,405 (68.3)                          | 5698 (67.7)        | 5890 (75.0)         | 7299 (65.2)           | 1701 (66.2)         |
| Positive                 | 146,516 (31.7)                          | 2717 (32.3)        | 1967 (25.0)         | 3893 (34.8)           | 867 (33.7)          |
| Missing                  | 84                                      | 1                  | 1                   | 1                     | 1                   |
| Surgery                  |                                        |                   |                     |                       |                     |
| Radical or total mastectomy | 199,975 (43.3)                       | 4301 (51.1)        | 3425 (43.6)         | 6299 (56.3)           | 1115 (43.4)         |
| Breast-conserving surgery | 223,197 (48.3)                        | 3510 (41.7)        | 3536 (45.0)         | 4326 (38.6)           | 1180 (45.9)         |
| Unspecified surgery      | 38,833                                  | 605                | 897                 | 568                   | 274                 |
| Radiation                |                                        |                   |                     |                       |                     |
| No                       | 213,565 (46.2)                          | 4185 (49.7)        | 3497 (44.5)         | 5797 (51.8)           | 1049 (40.8)         |
| Yes                      | 235,859 (51.1)                          | 4015 (47.7)        | 4218 (53.7)         | 5092 (45.5)           | 1476 (57.5)         |
| Unknown                  | 12,581                                  | 216               | 143                 | 304                   | 44                  |
| Person-years of follow-up|                                        |                   |                     |                       |                     |
| Mean (SD)                | 6.8 (4.9)                               | 6.9 (5.1)          | 8.2 (5.4)           | 6.6 (4.9)             | 7.3 (5.2)           |
| Median (IQR)             | 4 (2–6)                                 | 3 (2–6)           | 4 (2–6)            | 3 (2–5)              | 4 (2–6)            |
Table 2 continued

|                         | Non-Hispanic White women (n = 462,005) | Chinese (n = 8416) | Japanese (n = 7858) | Filipino (n = 11,193) | Hawaiian (n = 2569) |
|-------------------------|----------------------------------------|--------------------|---------------------|------------------------|---------------------|
| **Outcome status**      |                                        |                    |                     |                        |                     |
| Alive                   | 352,200 (76.2)                         | 7138 (84.8)        | 6339 (80.7)         | 9401 (84.0)            | 1935 (75.3)         |
| Died (all causes)       | 109,805 (23.8)                         | 1278 (15.2)        | 1519 (19.3)         | 1792 (16.0)            | 634 (24.7)          |
| Breast cancer-specific  | 46,116 (42.0)                          | 712 (55.7)         | 554 (36.5)          | 1061 (59.2)            | 288 (45.4)          |
| Cardiovascular          | 25,527 (23.2)                          | 207 (16.2)         | 381 (25.1)          | 272 (15.2)             | 140 (22.1)          |
| **Age at index breast cancer** |                                        |                    |                     |                        |                     |
| Mean (SD)               | 53.3 (11.9)                            | 52.6 (12.2)        | 53.4 (12.8)         | 55.0 (12.0)            | 54.0 (12.5)         |
| Median (IQR)            | 52 (45–62)                             | 51 (44–60)         | 53 (44–62)          | 55 (46–63)             | 52 (45–62)          |
| 20–49 years             | 1173 (42.6)                            | 1078 (44.7)        | 1180 (40.6)         | 318 (34.3)             | 2220 (40.4)         |
| 50–64 years             | 1060 (38.5)                            | 910 (37.8)         | 1127 (38.8)         | 402 (43.3)             | 2124 (38.7)         |
| 65–74 years             | 372 (13.5)                             | 286 (11.9)         | 434 (14.9)          | 150 (16.2)             | 750 (13.7)          |
| 75–85 years             | 135 (4.9)                              | 115 (4.8)          | 144 (5.0)           | 51 (5.5)               | 345 (6.3)           |
| 85+ years               | 15 (0.5)                               | 21 (0.9)           | 23 (0.8)            | 7 (0.8)                | 55 (1.0)            |
| **Birthplace**          |                                        |                    |                     |                        |                     |
| U.S.                    | 124 (4.5)                              | 24 (1.0)           | 135 (4.6)           | 82 (8.8)               | 543 (9.9)           |
| Non-U.S.                | 1792 (65.0)                            | 1637 (67.9)        | 1525 (52.4)         | 488 (52.6)             | 1333 (24.3)         |
| Unknown                 | 839                                    | 749                | 1248                | 358                    | 3618                |
| **Marital status**      |                                        |                    |                     |                        |                     |
| Single or never married | 275 (10.0)                             | 396 (16.4)         | 143 (4.9)           | 110 (11.9)             | 667 (12.1)          |
| Married or domestic partner | 2411 (87.5)                            | 1947 (80.8)        | 2699 (92.8)         | 793 (85.5)             | 4650 (84.6)         |
| Unknown                 | 69                                     | 67                 | 66                  | 25                     | 177                 |
| **AJCC stage**          |                                        |                    |                     |                        |                     |
| I                       | 1270 (46.1)                            | 1071 (44.4)        | 1195 (41.1)         | 341 (36.7)             | 2670 (48.6)         |
| II                      | 1085 (39.4)                            | 968 (40.2)         | 1192 (41.0)         | 395 (42.6)             | 2202 (40.1)         |
| III                     | 400 (14.5)                             | 371 (15.4)         | 521 (17.9)          | 192 (20.7)             | 622 (11.3)          |
| **Hormone receptor status** |                                        |                    |                     |                        |                     |
| ER(+)/PR(+)             | 1525 (55.4)                            | 1302 (54.0)        | 1722 (59.2)         | 606 (65.3)             | 3330 (60.6)         |
| ER(+)/PR(−)             | 263 (9.5)                              | 258 (10.7)         | 269 (9.3)           | 80 (8.6)               | 592 (10.8)          |
| ER(−)/PR(+)             | 55 (2.0)                               | 53 (2.2)           | 41 (1.4)            | 13 (1.4)               | 76 (1.4)            |
| ER(−)/PR(−)             | 620 (22.5)                             | 493 (20.5)         | 614 (21.1)          | 170 (18.3)             | 916 (16.7)          |
| Missing                 | 292                                    | 304                | 262                 | 59                     | 580                 |
| **Tumor size**          |                                        |                    |                     |                        |                     |
| <2 cm                   | 2209 (80.2)                            | 1922 (79.8)        | 2348 (80.7)         | 709 (76.4)             | 4671 (85.0)         |
| ≥2 cm                   | 537 (19.5)                             | 473 (19.6)         | 542 (18.6)          | 209 (22.5)             | 806 (14.7)          |
| Missing                 | 9                                      | 15                 | 18                  | 10                     | 17                  |
| **Lymph node status**   |                                        |                    |                     |                        |                     |
| Negative                | 1766 (64.1)                            | 1560 (64.7)        | 1749 (60.1)         | 538 (58.0)             | 3696 (67.3)         |
| Positive                | 989 (35.9)                             | 848 (35.2)         | 1157 (39.8)         | 390 (42.0)             | 1797 (32.7)         |
| Missing                 | 2                                      | 2                  |                     |                        |                     |
| **Surgery**             |                                        |                    |                     |                        |                     |
| Radical or total mastectomy | 1376 (49.9)                            | 1391 (57.7)        | 1425 (49.0)         | 459 (49.5)             | 2767 (50.4)         |
| Breast-conserving surgery | 1235 (44.8)                            | 940 (39.0)         | 1386 (47.7)         | 427 (46.0)             | 2569 (46.8)         |
| Unspecified surgery     | 144                                    | 79                 | 97                  | 42                     | 158                 |
| Radiation               |                                        |                    |                     |                        |                     |
| No                      | 1345 (48.8)                            | 1325 (55.0)        | 1288 (44.3)         | 442 (47.6)             | 2897 (52.7)         |
ethnicities. Hawaiian women experienced increased risk for cardiovascular-specific death following breast cancer in comparison to NHW women. We also found that compared to non-U.S. born women, API women born in the U.S. had higher risk of both cardiovascular and all-cause mortality following breast cancer.

The 5-year breast cancer survival rates of API women in the United States and some countries in Asia are over 80%, with India as an exception (Allemani et al. 2015). The influence of nativity and birthplace on health outcomes were evaluated in other smaller studies (Hedeen et al. 1999; Ziegler et al. 1993; Pineda et al. 2001; Franzini et al. 2001; Gomez et al. 2010). It is hypothesized that acculturation factors related to migration, such as change in diet, could explain differences in breast cancer survival. In a study by Pineda, et al. (Pineda et al. 2001), no differences in survival were found by place of birth among API women with BC in three SEER registries between 1973 and 1994. This study, however, was limited to Chinese, Japanese, and Filipino women only. In our study, using more recent years of follow up and information on women from other API ethnicities, we found that API breast cancer survivors born in the U.S. had increased risk for cardiovascular-specific and all-cause mortality.

Although not statistically significant, U.S.-born Filipino and Vietnamese women showed a possibly increased risk of all-cause mortality. This suggests that while overall breast cancer survival rates may be comparable, some factors associated with acculturation or U.S. residence may affect other important health outcomes. Differences in health beliefs and practices exist between Non-Hispanic White (NHW) and API women that may influence cancer risk and outcomes. Mammography screening varies considerably by API ethnicity and adherence to screening recommendations in these groups is further impacted by non-U.S. citizen status and having health insurance coverage (Gomez et al. 2007). In a U.S. population-based study (Gomez et al. 2004), API enrollees in a health maintenance organization had lower body mass index (BMI) and were less likely to report alcohol consumption and current or ever smoking. Further, fewer APIs engaged in physical activity compared to their NHW counterparts.
Fig. 1  Age-adjusted cumulative hazards of mortality among Non-Hispanic White and Asian/Pacific Islander women. a Breast cancer-specific mortality, b all-cause mortality, c cardiovascular mortality.
Fig. 2 Age-adjusted cumulative hazards of mortality by Asian/Pacific Islander ethnicity. a Breast cancer-specific mortality, b all-cause mortality, c cardiovascular mortality.
Table 3 Risk of all-cause, breast cancer-specific and cardiovascular mortality among Asian/Pacific Islander women compared to Non-Hispanic White women

|                                | Non-Hispanic White | All Asian/Pacific Islander women | Chinese | Japanese | Filipino | Hawaiian | Korean | Vietnamese | Asian Indian and Pakistani | Pacific Islander | Other Asian |
|--------------------------------|--------------------|----------------------------------|--------|----------|----------|----------|--------|------------|---------------------------|----------------|------------|
|                                | HR (95 % CI)       | HR (95 % CI)                     | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) |
| Age/stage-adjusted\(^a\)       |                   |                                 |         |           |           |           |        |            |                           |                |            |
| Multivariable-adjusted\(^b\)  |                   |                                 |         |           |           |           |        |            |                           |                |            |
| Breast cancer-specific mortality |                   |                                 |         |           |           |           |        |            |                           |                |            |
| Cardiovascular mortality       |                   |                                 |         |           |           |           |        |            |                           |                |            |
| All-cause mortality            |                   |                                 |         |           |           |           |        |            |                           |                |            |

All estimates are for comparisons of specific Asian/Pacific Islander groups to reference group of Non-Hispanic White women. Italics indicates statistical significance at \(P < 0.05\) after Bonferroni correction for multiple comparisons

\(^a\) Model with adjustment for year of diagnosis, SEER registry, age (20–49, 50–64, 65–74, 75–84, 85+ years) and AJCC stage (I, II, III)

\(^b\) Model with adjustment for year of diagnosis, SEER registry, age (20–49, 50–64, 65–74, 75–84, 85+ years), AJCC stage (I, II, III), birthplace (U.S., non-U.S., unknown), marital status (single or never married, married or domestic partner, unknown), hormone receptor status (ER+/PR+, ER+/PR–, ER–/PR+, ER–/PR–, unknown), tumor size (<2, ≥2 cm, unknown), lymph node status (negative, positive, unknown), surgical procedure (radical or total mastectomy, breast-conserving surgery, unspecified surgery), radiation (yes/no)

Table 4 Risk of all-cause, breast cancer-specific and cardiovascular mortality among U.S. born Asian/Pacific Islander women compared to non-U.S. born women

|                                | All Asian/Pacific Islander women | Chinese | Japanese | Filipino | Hawaiian | Korean | Vietnamese | Asian Indian and Pakistani | Pacific Islander | Other Asian |
|--------------------------------|----------------------------------|--------|----------|----------|----------|--------|------------|---------------------------|----------------|------------|
|                                | HR (95 % CI)                     | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) |
| Age/stage-adjusted\(^a\)       |                                 |         |           |           |           |        |            |                           |                |            |
| Multivariable-adjusted\(^b\)  |                                 |         |           |           |           |        |            |                           |                |            |
| Breast cancer-specific mortality |                                 |         |           |           |           |        |            |                           |                |            |
| Cardiovascular mortality       |                                 |         |           |           |           |        |            |                           |                |            |
| All-cause mortality            |                                 |         |           |           |           |        |            |                           |                |            |

All estimates are among women with documented birthplace in SEER for comparisons within specific Asian/Pacific Islander groups of U.S. born women to reference group of non-U.S. born women. Italics indicates statistical significance at \(P < 0.05\) after Bonferroni correction for multiple comparisons

\(^a\) Model with adjustment for year of diagnosis, SEER registry, age (20–49, 50–64, 65–74, 75–84, 85+ years) and AJCC stage (I, II, III)

\(^b\) Model with adjustment for year of diagnosis, SEER registry, age (20–49, 50–64, 65–74, 75–84, 85+ years) and AJCC stage (I, II, III), marital status (single or never married, married or domestic partner, unknown), hormone receptor status (ER+/PR+, ER+/PR–, ER–/PR+, ER–/PR–, unknown), tumor size (<2, ≥2 cm, unknown), lymph node status (negative, positive, unknown), surgical procedure (radical or total mastectomy, breast-conserving surgery, unspecified surgery), radiation (yes/no)

\(^c\) Not enough events to estimate cause-specific mortality
These characteristics also vary by API ethnicity. Japanese enrollees were more likely to have ever smoked and Filipinos were more likely to have smoked at an earlier age. Chinese and Japanese enrollees had lower BMI, while other API groups had similar or greater BMI compared to non-Hispanic Whites (Gomez et al. 2004). Many of these factors not only affect cancer outcomes but are important to risk of cardiovascular disease and other chronic conditions. With many potential survivorship years post-breast cancer and a likely history of treatment with cardiotoxic chemotherapy and radiation, cardiovascular risk is important to the aging population of API breast cancer survivors (Hooning et al. 2007).

Further research is needed to corroborate these findings and examine cultural factors, biobehavioral mechanisms and health care policies that impact breast cancer survival in different API women. If confirmed, our study has important public health implications. Understanding differences between women of different API ethnicities can help guide tailored interventions to improve outcomes in this heterogeneous group of breast cancer survivors. It is essential that aging women with a history of BC be able to manage the multiple chronic health concerns that follow their last cancer treatment. One way to approach this is by creating more customized survivorship care plans (SCP) for breast cancer survivors (Miller 2008). The purpose of creating breast cancer SCPs is to maximize the health outcomes of these patients during the difficult transition from the end of cancer treatment to care beyond their oncology provider (Hewitt et al. 2006).

According to a review of survivorship care in the cancer literature, less than one half of National Cancer Institute-designated cancer centers provide SCPs to breast cancer survivors. This is partly due to the resources, time and commitment that come with survivorship care planning (Salz et al. 2012). Although these barriers need to be overcome in order for the SCP to be widely adopted, by working towards making these plans more personalized, people may be more likely to utilize them and successfully manage their health post-breast cancer. In a study that explored the experiences of South Asian breast cancer survivors post-treatment (Singh-Carlson et al. 2013), researchers found that this group may have certain spiritual and language-specific support needs that should be taken into consideration when creating a SCP. From our results, we see that certain groups, such as the Hawaiians, may be at greater risk for cardiovascular-specific mortality. This may signal a need to incorporate more regular or targeted surveillance for cardiovascular risk factors in breast cancer survivorship care for some API women.

The distribution of subtypes may differ among ethnic groups, which may be an indicator of breast cancer prognosis and survival (Gomez et al. 2014; Parise and Caggiano 2014; Telli et al. 2011). In addition to tailored interventions and survivorship care plans, these results should spur discussion on ways to improve access to health care and to explore the biology of breast cancer in this heterogeneous group.

Our study has several limitations. We utilized registry-collected data from SEER only, and 36.3 % of the API women did not report their place of birth. Information on other factors that could influence survival after breast cancer including individual-level data measuring dietary intake and socioeconomic status were not available. Other reports have hypothesized that low dietary fat intake among Japanese women partly explains the greater survival observed compared to other racial and ethnic groups in the U.S., although epidemiological studies have not found consistent associations (Holmes et al. 1999; Nomura et al. 1991; Lands et al. 1990).

Despite these limitations, our study has several strengths. We utilized data on a large number of API breast cancer survivors from population-based cancer registries in different regions of the U.S. In evaluating disaggregated ethnic groups of API breast cancer survivors, we report on outcomes among women less represented in the cancer and health disparities literature such as Pacific Islander women.

Conclusion

In conclusion, aggregation of API women with breast cancer can mask disparities in cancer-specific, cardiovascular- and all-cause mortality. Our findings suggest that specific API populations are at higher risk for mortality after breast cancer diagnosis. With further research and understanding of the API population, these findings should translate to public health practice.

Authors’ contributions

PAS and GSC conceived of the study, collected the data and performed statistical analyses and prepared the first draft of the results tables, figures and manuscript. NYK participated in the design of the study and interpretation of results. All authors read and approved the final manuscript.

Author details

1 Department of Epidemiology and Biostatistics, University of Illinois at Chicago, 1603 W Taylor St., Chicago, IL 60612, USA. 2 Section of Hematology Oncology, Boston University, Boston Medical Center, 725 Albany St., Boston, MA 02118, USA. 3 Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA. 4 Population Health, Behavior and Outcomes Program, University of Illinois Cancer Center, 1801 W Taylor St., Chicago, IL 60612, USA.

Acknowledgements

This work was supported by the Carter Disparities Fund at Boston Medical Center.

Competing interests

The authors declare that they have no competing interests.

Received: 13 January 2016 Accepted: 15 January 2016
Published online: 26 January 2016
